STAT5A

Across TCGA pan-cancer cohorts, STAT5A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of STAT5A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where STAT5A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STAT5A is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where STAT5A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STAT5A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.589	<.001	12	view →
LUAD	Male	II,III,IV	−0.367	<.001	9	view →
LSCC	Male	III,IV	−0.441	<.001	8	view →
HNSC	All	III,IV	−0.287	<.001	8	view →
COAD	All	II,III,IV	−0.142	.001	7	view →
PDAC	All	All	+0.165	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

STAT5A–CCRCC

Open the CCRCC breakdown →